NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.